Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Debt (2020)

Vistagen Therapeutics' Total Debt history spans 3 years, with the latest figure at $87300.0 for Q3 2020.

  • For Q3 2020, Total Debt changed N/A year-over-year to $87300.0; the TTM value through Sep 2020 reached $87300.0, changed N/A, while the annual FY2016 figure was $27200.0, N/A changed from the prior year.
  • Total Debt for Q3 2020 was $87300.0 at Vistagen Therapeutics, down from $124700.0 in the prior quarter.
  • Across five years, Total Debt topped out at $124700.0 in Q2 2020 and bottomed at $27200.0 in Q1 2016.